GLYcemic Control Evaluation by Continuous Glucose Monitor Compared With a1C in Left Ventricular Assist Device-supported Patients (GLYCEM1C-LVAD)
The GLYCEM1C-LVAD study, sponsored by Mayo Clinic, aims to validate the use of hemoglobin A1c as a measure of glycemic control in patients with LVADs, a population that may experience unique challenges in diabetes management. The study leverages the Freestyle Libre 3 Continuous Glucose Monitor (CGM) to provide real-time glucose data, potentially leading to improved patient outcomes through better glycemic control. The findings could enhance the market positioning of CGM devices in specialized patient populations, indicating a growing need for tailored diabetes management solutions. The study's outcomes may influence future guidelines and reimbursement policies, thereby impacting market dynamics and competitive positioning among diabetes management technologies.
Indication: Type 2 Diabetes Mellitus
Modality: medical device
Target: Continuous Glucose Monitoring in Type 2 Diabetes Mellitus patients with Left Ventricular Assist Devices (LVADs)
Sponsor: Mayo Clinic
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 14, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Continuous Glucose Monitoring in Type 2 Diabetes Mellitus patients with Left Ventricular Assist Devices (LVADs)
View original source fields
Condition raw: Type 2 Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Condition normalized: Type 2 Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Modality raw: medical device
Modality normalized: medical device
Target raw: Continuous Glucose Monitoring in Type 2 Diabetes Mellitus patients with Left Ventricular Assist Devices (LVADs)
Target normalized: Continuous Glucose Monitoring in Type 2 Diabetes Mellitus patients with Left Ventricular Assist Devices (LVADs)